Cost of patients with primary open-angle glaucoma: a retrospective study of commercial insurance claims data.

[1]  R. Klein,et al.  The economic burden of major adult visual disorders in the United States. , 2006, Archives of ophthalmology.

[2]  C. Birbara,et al.  Frequency, Predictors, and Economic Impact of Upward Dose Adjustment of Infliximab in Managed Care Patients With Rheumatoid Arthritis , 2005, Journal of managed care pharmacy : JMCP.

[3]  C. Alexander,et al.  End-stage renal disease-associated managed care costs among patients with and without diabetes. , 2004, Diabetes care.

[4]  D. Ollendorf,et al.  Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study , 2004, BMC musculoskeletal disorders.

[5]  M. C. Leske,et al.  Prevalence of open-angle glaucoma among adults in the United States. , 2004, Archives of ophthalmology.

[6]  Philip P. Chen.  Risk and risk factors for blindness from glaucoma , 2004, Current opinion in ophthalmology.

[7]  D. Ollendorf,et al.  Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia. , 2004, MedGenMed : Medscape general medicine.

[8]  T. Einarson,et al.  Cost of Glaucoma in Canada: Analyses Based on Visual Field and Physician's Assessment , 2003, Journal of glaucoma.

[9]  James S Distelhorst,et al.  Open-angle glaucoma. , 2003, American family physician.

[10]  G. Kobelt.  Health Economics, Economic Evaluation, and Glaucoma , 2002, Journal of glaucoma.

[11]  S. Vold,et al.  Cost Analysis of Glaucoma Medications: A 3-Year Review , 2002, Journal of glaucoma.

[12]  J. Oostenbrink,et al.  Resource Use and Costs of Patients With Glaucoma or Ocular Hypertension: A One-year Study Based on Retrospective Chart Review in the Netherlands , 2001, Journal of glaucoma.

[13]  W. C. Stewart,et al.  Daily cost of newer glaucoma agents. , 1999, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[14]  G. Kobelt-Nguyen,et al.  Costs of treating primary open-angle glaucoma and ocular hypertension: a retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States. , 1998, Journal of glaucoma.

[15]  R G Fiscella,et al.  Costs of glaucoma medications. , 1998, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[16]  A. Coleman,et al.  Use of insurance claims databases to evaluate the outcomes of ophthalmic surgery. , 1997, Survey of ophthalmology.

[17]  B. Virnig,et al.  The Medicare-HMO revolving door--the healthy go in and the sick go out. , 1997, The New England journal of medicine.

[18]  Keister Lw.  Managed care's 'revolving door'. How it affects your practice. , 1996 .

[19]  Pontious Jm,et al.  Episode treatment groups: an illness classification and episode building system--Part II. , 1996 .

[20]  A. Sommer,et al.  Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. , 1991, JAMA.

[21]  Philip P. Chen,et al.  A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma. , 2006, Archives of ophthalmology.

[22]  H. Quigley,et al.  Models of open-angle glaucoma prevalence and incidence in the United States. , 1997, Investigative ophthalmology & visual science.